Keywords of research interests

Clinical Pharmacy; Pharmacokinetics/pharmacodynamics; Pharmacogenomics; Personalized medicine

Curriculum Vitae

Education

Sept 1978-Jul 1982  Second Military AdMedical University, College of Pharmacy, Shanghai, China. B.S. in Pharmacy

Feb 1983-Dec 1985  Second Military Medical University, Laboratory for Antimalarial Drug Research, Shanghai, China. M.S. in Medicinal Chemistry

Aug 1997-Jul 2000  Nanjing Medical University, Institute of Clinical Pharmacology, Ph.D. in Clinical Pharmacology

Oct 2000-Oct 2001  University of Kentucky, College of Pharmacy, Postdoctoral fellow in Pharmacogenetics

Professional Experiences

Jul 1986-Apr 2003  Pharmacist, Nanjing Jinling Hospital

Apr 2003-May 2008  Director and Professor, Department of Pharmacy, Ruijin Hospital affiliated Shanghai Jiaotong. University, School of Medicine

Jun 2008-present  Director and Professor, Department of Clinical Pharmacy, Fudan University, School of Pharmacy

Teaching Activities

1. Advisor for M.S. and Ph.D. Students (Clinical Pharmacy)

2. Coordinator for School’s Clinical Pharmacy Program

3. Courses in charge for bachelor degree: Introduction to Clinical Pharmacy; Clinical Pharmacotherapy I & II

4. Courses in charge for graduate student: Clinical Drug Evaluation; Clinical Pharmacotherapy; Pharmacogenomics

Grants & Projects

1. “Study on clinical pharmacy professional curriculum and teaching system”, 2010 Major Project of Chinese High Education Association Medical Education Buru, 4.500, 2011.1-2012.12, Principal Investigator.  

2. “clinical Pharmacotherapy-lecture and textbook”，2012 Shanghai postgraduate education funding, SHGS-KC-2011001，100,000, Jan 2012-Dec. 2012，Principal Investigator.

3. “Effect of K-RAS mutation of ABC transporter mediated multi-drug resistance and its mechanism study”, National Natural Science Foundation of China, 81102459, 220,000, Jan. 2012-Dec. 2014, Chief Investigator.

4. “A novel Bio-PK/PD simulation system and its application in metabolism-mediated toxicity of SPRC”， National Natural Science Foundation of China, 81273584，700,000, Jan. 2013-Dec. 2016, Principle Investigator.

5. “K-ras mutation mediated gemcitabine resistance in pancreatic cancer and its mechanism”, Doctoral Research Funding, 20130071110069，120,000，2014.1-2016.12，Principle Investigator.

6. “Prediction of CYP mediated DDI by in vitro dynamic Bio-PK/PD system combined with PBPK modeling”，National Natural Science Foundation of China, 81673501，600,000, Jan. 2017-Dec. 2020, Principle Investigator.

7. “Prediction of warfarin personalized dosage based on DDI and PBPK modeling”, National Natural Science Foundation of China (International Collaboration Project), 81711540310，2017.07-2019.06，Principle Investigator.

Awards & Honors

1. PLA Science and Technology Advances Award (second class)(1991)

2. PLA Science and Technology Advances Award (second class)(1996)

3. Government Special Stipend Award, Ministry of State, China (2000)

4. PLA Science and Technology Advances Award (second class)(2001)

5. National Award of 100 Excellent Ph.D. Thesis (2002)

6. Shanghai Pharmaceutical Association Science and Technology Award (third class)(2007)

7. Fudan University Postgraduate Teaching Achievement Award (second class)(2012)

8. Shanghai Teaching Achievement Award for Higher Education (second class)(2018)

Memberships

1. Vice Chair of Pharmcoepidemiology Committee of Chinese Pharmaceutical Association

2. Commission of Clinical Pharmacology Committee of Chinese Pharmacology Association

3. Commission of Drug Metabolism Committee of Chinese Pharmacology Association

4. Chair of Drug Metabolism Committee of Shanghai Pharmacology Association

5. Vice Editor-in-Chief of “China Pharmacist Journal”

6. Editor of “Chinese Journal of Hospital Pharmacy”

Invited Presentations

1. “Influence of Genetic and Non-genetic Factors on the Plasma Concentrations of the Clopidogrel Metabolite (SR26334) among Chinese Patients”， 29th International Pharmacoepidemiology Congress, poster, Montreal, Canada, Aug. 24~28, 2013.

2. “New model of bachelor/master/doctoral training system in Clinical pharmacy”, China Higher Education Forum 2014, Plenary session speaker, Kunming, 2014.12

3. “Application of a new dynamic model to predict the in vitro intrinsic clearance of tolbutamide using rat mircosomes encapsulated in a Fab hydrogel”，11th National Conference of Drug and Xenobiotic Metabolism, Plenary session speaker，Jinan, 2015.10

4. “A China-US Clinical Pharmacy Exchange Program for Experiential Education: a 6-Year Report”， 2015 AACP Annual Meeting (Global Pharmacy Education Special Interest Group)，poster & speaker, National Harbor, United States, July 11 - July 15, 2015.  

5. “Application of a new dynamic model to predict the in vitro intrinsic clearance of tolbutamide using rat mircosomes encapsulated in a Fab hydrogel”，201511th National Meeting of Drug Metabolism and Xenobiotics，Plenary session speaker，Jinan, Shandong, 2015.10

6. “Drug activity screening based on microsomes-hydrogel system in predicting metabolism induced antitumor activity of oroxylin A”, 11th International Society for the Study of Xenobiotics (ISSX) meeting, Poster, Busan, Republic of Korea, 2016.6.12~16

7. “Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients”，6th Pharmaceutical Science World Congress, Poster, Stockholm, Sweden, May 21~24, 2017.

8. “Pharmacogenomics and cancer personalized medicine”, 4th China Pharmacogenomics Congress, Plenary session speaker，Xian, China, 2017;10.26~28.

Selected Publications（latest 5 yrs，<20 papers）

1. Yang H, Zheng Y, Zhao B, Shao T, Shi Q, Zhou N, Cai WM*. Encapsulation of liver microsomes into a thermosensitive hydrogel for characterization of drug metabolism and toxicity. Biomaterials 2013; 34: 9770~9778.

2. Ma G, Lin J, Cai W, Bo Tan, Xiaoqiang Xiang,Ying Zhang, Peng Zhang. Simultaneous determination of bilirubin and its glucuronides in liver microsomes and recombinant UGT1A1 enzyme incubation systems by HPLC method and its application to bilirubin glucuronidation studies. Journal of Pharmaceutical and Biomedical Analysis. 2014; 92C:149-59.

3. Tan B, Cai W, Zhang J, Zhou N, Ma G, Yang P, Zhu Q, Zhu Y. Identification of UDP-glucuronosyltransferase isoforms responsible for leonurine glucuronidation in human liver and intestinal microsomes. Xenobiotica 2014; 44(5): 775~784. Co-first author

4. Shao T, Zheng Y, Zhao B, Li T, Cheng K, Cai W. Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity. Sci China Life Sci. 2014, 57(10):1011-7.

5. SEQC/MAQC-III Consortium. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. Nature Biotechenology 2014; 32(9): 903~914. Co-author

6. Guo Ma, Lin Zhang, Peng Zhang, Xingfei Bao, Ning Zhou, Qingling Shi, Yuanting Zheng, Hongrui Liu,Fengjiao Bu, Ying Zhang, Wenjie Huang, Fen Wang, Yizhun Zhu, and Weimin Cai*. Physicochemical characteristics and gastrointestinal absorption behaviors of S-propargyl-cysteine, a potential new drug candidate for cardiovascular protection and antitumor treatment. Xenobiotica 2015; 45(4): 322-34.

7. Yuan-ting ZHENG, Hui-ying YANG, Tao LI, Bei ZHAO, Teng-fei SHAO, Xiao-qiang XIANG, Wei-min CAI* Synergism of Amiloride and Erlotinib through Inhibiting PI3K/AKT Signaling Pathway in Pancreatic Cancer Cells. Acta Pharmacol Sin 2015; 36(5):614-26.  

8. Meng X, Yin K, Wang J, Dong P, Liu L, Shen Y, Shen L, Ma Q, Lu H, Cai WM*. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection. PLoS One. 2015 Jun 24; 10(6):e0130583. doi: 10.1371/journal.pone.0130583.

9. Ning Zhou, Yuanting Zheng, Junfen Xing, Huiying Yang, Hanmei Chen, Xiaoqiang Xiang, Jing Liu, Shanshan Tong, Bin Zhu, and Weimin Cai*. Application of a New Dynamic Model to Predict the In Vitro Intrinsic Clearance of Tolbutamide Using Rat Microsomes Encapsulated in a Fab Hydrogel. Drug Met Disp 2016; 44: 40-49.

10. Huiying Yang, Jianfeng Li, Yuanting Zheng, Lu Zhou, Shanshan Tong, Bei Zhao, and Weimin Cai*. Drug activity screening based on microsomes-hydrogel system in predicting metabolism induced antitumor activity of oroxylin A. Scientific Reports 2016, Published: 24 February 2016（DOI: 10.1038/srep21604.

11. Tao Li, Yuanting Zheng, Hong Sun1, Rongyuan Zhuang, Jing Liu, Weimin Cai*. K-RAS mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: A systematic review with meta-analysis. Medical Oncology 2016, 33:61, DOI 10.1007/s12032-016-0777-1.

12. Sun H, Zhuang RY, Li T, Zheng YT, Cai WM*. No association Between Calcium Channel Blockers and Survival in Patients with Cancer: A systematic Review and Meta-analysis. Asian Pac J Cancer Prev 2016, 17 (8), 3917-3921.

13. Tong SS, Sun H, Xue CF, Chen H, Liu J, Yang H, Zhou N. Xiang XQ, Cai WM*. Establishment and assessment of a novel in vitro Bio-PK/PD system in predicting the in vivo pharmacokinetics and pharmacodynamics of cyclophosphamide. Xenobiotica 2018；48(4): 368-375. Epub 2017; Jun 6. doi: 10.1080/00498254. 2017.1330576.

14. Ma G, Zhang Y, Chen WY, Tang ZF, Xin XM, Yang P, Liu XQ, Cai WM*, Hu M*. Inhibition of Human UGT1A1-Mediated Bilirubin Glucuronidation by Polyphenolic Acids Impact Safety of Popular Salvianolic Acid A/B Containing Drugs and Herbal Products. Mol Pharmaceutics 2017; 14: 2952-66.

15. Xue CF, Zhang XJ, Cai WM*. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model. Pharmaceutics 2018；10, 1; doi:10.3390/pharmaceutics10010001

16. Wang PP,  Lv QY, Mao YM, Zhang CZ, Bao CX, Sun S, Chen HM, Yi ZH, Cai WM*. HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients.  J Affective Disorders 2018; 228: 222~228.

Patents

“Encapsulation of liver microsomes into a thermosensitive hydrogel for characterization of drug metabolism and toxicity”, China Patent, 201310310303.9,  2018.1.9